Lexology December 8, 2023
The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and Bluebird Bio’s Lyfgenia®, the first cell-based gene therapies to treat sickle cell disease in patients 12 years and older. Casgevy® is the first FDA-approved treatment that uses CRISPR/Cas9 to genetically modify a patients’ hematopoietic stem cells. Lyfgenia® uses a lentiviral vector for genetic modification and is approved to treat patients with a history of vaso-occlusive events.
In each instance,...
Today's Sponsors
Today's Sponsor